ValenzaBio nabs $70m Series A

ValenzaBio Inc, a developer of monoclonal antibody therapeutics for autoimmune and inflammatory indications, has closed $70 million in Series A financing.

ValenzaBio Inc, a developer of monoclonal antibody therapeutics for autoimmune and inflammatory indications, has closed $70 million in Series A financing. The investors included Fidelity Management & Research Company, LLC, and Surveyor Capital.

Source: Press Release